SecBot SecBot
Biotech Drug Report Generated Jul 1, 2026

AGAMREE

CPRX·CATALYST PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercialized (US launch March 2024)
Why 4/10
AGAMREE is already FDA-approved (Oct 2023) and commercially available, with no pending PDUFA or pivotal readout for new indications in the next ~12 months. The SUMMIT long-term safety registry is observational and not a stock-moving binary. AGAMREE is ~20% of Catalyst's revenue mix and growing, but the company's defining binary events (approval, launch) have passed.
Actionable Insight NEUTRAL

For a non-medical investor, AGAMREE is a commercial-stage asset already contributing meaningful revenue growth ($117M in 2025, guiding $140-150M for 2026). There's no binary FDA catalyst ahead, so the stock moves on quarterly sales execution and overall company performance. Watch quarterly AGAMREE revenue growth rates and any news about label expansion studies (DMD is the only approved indication). Multiple analysts downgraded CPRX to Hold/Neutral recently, suggesting the easy money from the approval catalyst is behind it.

Price Chart

Loading chart...

Executive Summary

AGAMREE (vamorolone) is a first-in-class dissociative corticosteroid approved by the FDA in October 2023 for Duchenne Muscular Dystrophy (DMD) in patients aged 2 years and older. Catalyst Pharmaceuticals (NASDAQ: CPRX) holds exclusive North American commercialization rights. The drug generated $117.1M in US net revenue in 2025 (up 154% YoY), and Catalyst guides $140-150M for 2026. It competes against standard corticosteroids (prednisone, deflazacort/Emflaza) with a differentiated safety profile. Since AGAMREE is already approved and commercializing with no imminent regulatory binary, the stock catalyst shifts to commercial execution and potential future label expansion. CPRX has been downgraded by multiple analysts recently, and the stock trades near its 52-week high.

How It Works

AGAMREE is a "dissociative steroid", a new type of corticosteroid designed to keep the muscle-strengthening and anti-inflammatory benefits of traditional steroids (like prednisone) while reducing the nasty side effects. In Duchenne muscular dystrophy, it helps boys maintain muscle function and delay loss of the ability to walk, but with less stunting of growth and better bone health compared to standard steroids.

Trial Status

AGAMREE was FDA-approved on October 26, 2023 based on the pivotal Phase 2b VISION-DMD study plus open-label extension safety data. A post-marketing SUMMIT registry study (NCT06564974) is actively recruiting to observe long-term safety and quality-of-life outcomes in DMD patients over 5 years. Long-term data presented at MDA 2026 confirmed comparable efficacy to traditional corticosteroids for up to 8 years with meaningful safety advantages (normal growth preserved).

The Two-Sided Case

▲ Bull Case5
AGAMREE revenue grew 154% YoY in 2025 to $117.1M, and 2026 guidance of $140-150M implies another ~20-28% growth, strong commercial momentum for a recently launched drug.
Differentiated safety profile (better growth, bone health vs traditional corticosteroids) creates a compelling value proposition that could drive continued share gains in the DMD corticosteroid market.
Catalyst holds the license for additional potential indications beyond DMD, which could expand the addressable market. The company has $709M cash and no debt, providing ample resources for lifecycle management.
Long-term data (up to 8 years) presented at MDA 2026 confirmed comparable efficacy to prednisone and deflazacort with meaningful safety advantages, strengthens the competitive positioning vs generic alternatives.
Institutional interest remains strong with top holders like BlackRock ($465M), Vanguard ($206M), and State Street ($170M) as of Q1 2026, and Point72 opened a new position.
▼ Bear Case5
Already approved, the defining binary catalyst (FDA approval) has passed. Without a pending regulatory decision or pivotal readout, the stock lacks a near-term binary event to drive outsized gains from this asset.
Competes against cheap generic corticosteroids (prednisone) and Emflaza (deflazacort), which have decades of real-world use. Payers may resist switching to a higher-cost branded option.
Catalyst withdrew 2026 financial guidance and canceled its Q1 2026 earnings call in May 2026, a bearish signal that created uncertainty about the company's outlook and led to multiple analyst downgrades.
Multiple analysts downgraded CPRX recently: HC Wainwright (Buy→Neutral), Citigroup (Buy→Neutral), and Stephens (Overweight→Equal-Weight), reflecting diminished near-term catalyst visibility.
At ~$31.43, CPRX trades near its 52-week high ($32.56) with a quant composite score of -71 and RSI of 72.1 (technically overbought territory), suggesting limited near-term upside.

Upcoming Catalysts

  • Quarterly earnings reports, key metric is AGAMREE revenue growth trajectory vs guidance of $140-150M for 2026
  • Potential label expansion studies for other indications (Catalyst holds license for additional indications beyond DMD)
  • Long-term SUMMIT registry study data readouts
  • European market expansion updates (Santhera leading rest-of-world commercialization)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CATALYST PHARMACEUTICALS, INC. DEFA14A CPRX ·Originating report

Sources · 10

Hover a chip for the title
1 en.wikipedia.org2 fda.gov3 santhera.com4 ir.catalystpharma.com5 investing.com6 biospace.com7 fiercepharma.com8 clinicaltrials.gov9 globenewswire.com10 biospace.com